PMID- 30701742
OWN - NLM
STAT- MEDLINE
DCOM- 20190228
LR  - 20190228
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 90
IP  - 9
DP  - 2018 Sep 20
TI  - Proton pump inhibitors receiving and prognosis of patients after scheduled 
      percutaneous coronary interventions.
PG  - 92-100
LID - 10.26442/terarkh201890992-100 [doi]
AB  - AIM: The urgency of the study is determined by the lack of data necessary in 
      order to assess the safety of prolonged use of proton pump inhibitors (PPI) in 
      patients with IHD combined with anti-aggregant therapy. The aim of the study was 
      to study the relationship between the use of PPI and the risk of thrombotic 
      complications in patients undergoing planned procedures of percutaneous coronary 
      interventions (PCI) and receiving dual antiplatelet therapy. MATERIALS AND 
      METHODS: The study is a prospective register of patients who successfully 
      underwent planned percutaneous coronary intervention (PCI). The effect of PPI 
      (omeprazole and pantoprazole) on the frequency of the combined end point 
      cardiovascular death, ACS, AI, TIA, peripheral arterial thrombosis and PE was 
      assessed using the Log-Rank criterion, as well as in a multivariate analysis (Cox 
      proportional risk regression model). RESULTS: A total of 391 patients were 
      included in the study (23.1% women, mean age 61.2 years +/- 10.4 years). The median 
      duration of follow-up was 18 months. During this period of time, 34 adverse 
      events were recorded. Log-Rank analysis showed that the proportion of patients 
      without adverse events in the omeprazole group was significantly lower in 
      comparison with patients who did not receive PPI (0.56 vs. 0.84, Log-Rank 
      p=0.003), and for pantoprazole no such pattern was found (0.89 against 0.84, 
      Log-Rank p=0.21). The average level of residual platelet reactivity (ORT), as 
      well as the number of patients with high ORT (> 208 PRU), did not differ 
      significantly between the groups of omeprazole, pantoprazole and the group of 
      patients not receiving PPI. According to multivariate analysis, omeprazole was an 
      independent predictor of thrombotic complications after a planned PCI (OR 3.75, 
      95% confidence interval 1.72-8.17, p=----0.0009). CONCLUSION: Long-term use of 
      omeprazole (at least 30 days) is an independent predictor of thrombotic 
      complications in patients who underwent planned PCI.
FAU - Komarov, A L
AU  - Komarov AL
AD  - Department of Clinical Problems of Atherothrombosis of the National Medical 
      Research Center for Cardiology, Moscow, Russia.
FAU - Shakhmatova, O O
AU  - Shakhmatova OO
AD  - Department of Clinical Problems of Atherothrombosis of the National Medical 
      Research Center for Cardiology, Moscow, Russia.
FAU - Muraseeva, V G
AU  - Muraseeva VG
AD  - Department of Clinical Problems of Atherothrombosis of the National Medical 
      Research Center for Cardiology, Moscow, Russia.
FAU - Novikova, E S
AU  - Novikova ES
AD  - Department of Clinical Problems of Atherothrombosis of the National Medical 
      Research Center for Cardiology, Moscow, Russia.
FAU - Guskova, E V
AU  - Guskova EV
AD  - Pirogov National Medical and Surgical Center, Moscow, Russia.
FAU - Panchenko, E P
AU  - Panchenko EP
AD  - Department of Clinical Problems of Atherothrombosis of the National Medical 
      Research Center for Cardiology, Moscow, Russia.
LA  - eng
PT  - Journal Article
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Acute Coronary Syndrome/etiology/*surgery
MH  - Aged
MH  - Coronary Restenosis/diagnosis/etiology/*prevention & control
MH  - Drug Therapy, Combination/methods
MH  - Female
MH  - *Gastrointestinal Hemorrhage/chemically induced/prevention & control
MH  - Humans
MH  - Long Term Adverse Effects/chemically induced/prevention & control
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/complications/*drug therapy
MH  - *Percutaneous Coronary Intervention/adverse effects/methods
MH  - *Platelet Aggregation Inhibitors/administration & dosage/adverse effects
MH  - Prognosis
MH  - Prospective Studies
MH  - *Proton Pump Inhibitors/administration & dosage/adverse effects
MH  - Registries/statistics & numerical data
MH  - Risk Adjustment
MH  - Russia
OTO - NOTNLM
OT  - IHD
OT  - omeprazole
OT  - pantoprazole
OT  - percutaneous coronary interventions
OT  - proton pump inhibitors
OT  - risk of cardiovascular complications
EDAT- 2019/02/01 06:00
MHDA- 2019/03/01 06:00
CRDT- 2019/02/01 06:00
PHST- 2019/02/01 06:00 [entrez]
PHST- 2019/02/01 06:00 [pubmed]
PHST- 2019/03/01 06:00 [medline]
AID - 10.26442/terarkh201890992-100 [doi]
PST - ppublish
SO  - Ter Arkh. 2018 Sep 20;90(9):92-100. doi: 10.26442/terarkh201890992-100.